U.S. Bio Company Executive Sells Millions in Shares Immediately After Exercising Stock Options

New Amsterdam Pharma Co. N.V.’s Chief Accounting Officer (CAO), Louise Frederika Kooij, exercised a large block of stock options on January 23 and 26 and then immediately sold most of the common shares acquired, according to a recent filing. The total value of the shares sold is estimated at approximately $2.42 million (about KRW 3.3 billion). After these transactions, she still holds roughly $800,000 (around KRW 1.1 billion) worth of common stock.

In an early‐January investor presentation, the company said it expects a European Medicines Agency (EMA) decision on approval of its cholesterol‐lowering combination therapy—obicetrapib plus ezetimibe—sometime in the second half of 2026. It also reported that, as of the end of 2025, its cash, cash equivalents and marketable securities balance stood at about $729 million (around KRW 980 billion).

New Amsterdam Pharma Co. N.V. (Nasdaq: NAMS) is a late‐stage biotech firm listed on Nasdaq, focused on developing next‐generation lipid treatments centered on its oral CETP inhibitor obicetrapib for patients with high LDL cholesterol and elevated cardiovascular risk. Over the past several years, the company has expanded its Phase III program and grown into a multi‐billion‐dollar market‐cap biotech, while also conducting early‐stage clinical trials in Alzheimer’s disease.